Filler G-prime: what a rheology number can—and cannot—tell you

G-prime, written G′, is a measure of a filler gel’s elastic response under specified test conditions. A higher value is not a universal “better filler” score: the number depends on the method and must be interpreted alongside other material properties, the tissue, placement, and treatment goal. It does not establish an FDA-approved use or guarantee a clinical result.¹²³

Read the axis before reading the ranking

Rheology is the study of how a material deforms and flows. In a filler chart, G′ describes an elastic component of that behavior; other measurements describe viscous behavior or the combined response. A chart becomes less informative when its testing conditions disappear.

An original study tested 35 hyaluronic-acid filler products in an independent laboratory across a range of angular frequencies. The measured properties changed with frequency. That finding is a reason to preserve the experimental context, not to shop from one detached number.¹

If a clinic shows a G-prime chart, ask which study supplied it and whether every entry was measured using the same method. A number copied from one manufacturer’s document may not be directly comparable with a number from a different laboratory or testing setup.

Separate a material measurement from a clinical claim

A laboratory result can help explain a clinician’s reasoning. It cannot replace the evidence required for the other three statements. Ask the speaker to identify when the discussion moves from a measurement to an interpretation.

The same caution applies to “lift.” A gel resisting deformation on a test instrument is not a direct measurement of how much a person’s cheek will change. A visible outcome includes the person’s anatomy and the actual procedure, not just the material in an unopened syringe.

One useful property is not the whole material

Clinical research has explored connections between filler rheology, tissue integration, and aesthetic outcomes. These studies examine particular products, populations, methods, and endpoints. They do not establish that a single property predicts all outcomes in every treatment area.²

Ask how the proposed filler is expected to behave in the selected tissue: what feature is being changed, what movement matters, and which tradeoffs the clinician is considering. The answer should be specific enough to explain the choice without turning into a product leaderboard.

The material-family guide handles a different question—how HA, PLLA, and calcium-hydroxylapatite products differ. A G-prime comparison between selected HA gels should not be stretched into a claim that all fillers share the same mechanism or reversibility.

Check which product the chart actually names

Product families can contain several formulations. Record the full product name, not merely the brand family. Ask whether the chart describes the version being offered and whether its study examined the proposed use.

Also check the purpose of the document. A manufacturer’s technical sheet, a laboratory experiment, a clinical trial, and FDA labeling may all contain useful information, but they answer different questions. None becomes an independent head-to-head comparison simply because it has a graph.

If the clinician cites an outcome study, ask what was measured and over what period. A rating of appearance, an imaging observation, and a patient satisfaction score should remain identifiable rather than being compressed into “scientifically the best.”

Keep the safety conversation outside the stiffness score

FDA describes important filler risks, including unintended injection into a blood vessel, and emphasizes product-specific uses and information.³ A higher or lower G-prime value does not remove the need for an appropriately qualified clinician, informed consent, and a complication-response plan.

Likewise, a claim that a gel feels soft does not make it universally suitable for a mobile area, and a claim that it is firm does not establish that it should be placed deeply. Those are clinical decisions requiring the exact product and anatomy. Treomark does not translate a chart into an injection plan.

Turn the chart into a better consultation

Bring three questions: “Were these numbers obtained under comparable conditions?”, “Which property matters for my stated goal?”, and “What evidence supports the outcome you expect in this area?”

A useful explanation connects the chart to a specific choice while acknowledging what the chart cannot predict. If the only rationale is that one number is the highest, ask for the missing clinical reasoning before purchasing treatment.